Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_446
Snippet: Human complement inhibitors, C3-inhibitor (Compstatin) and human recombinant C1-esterase Inhibitor (C1-INH) were evaluated using an in vitro hemolytic assay. Antibody-coated sheep erythrocytes were exposed to canine complement with and without inhibitors. Dose curves were generated by plotting the percentage of hemolysis against inhibitor concentration. Complement activation in samples from 11 healthy and 13 dogs with IMHA was determined using an.....
Document: Human complement inhibitors, C3-inhibitor (Compstatin) and human recombinant C1-esterase Inhibitor (C1-INH) were evaluated using an in vitro hemolytic assay. Antibody-coated sheep erythrocytes were exposed to canine complement with and without inhibitors. Dose curves were generated by plotting the percentage of hemolysis against inhibitor concentration. Complement activation in samples from 11 healthy and 13 dogs with IMHA was determined using an ELISA for detection of Terminal Complement Complex C5b-9 (TCC C5b9). The concentration of TCC C5b9 in patient samples was extrapolated from a standard curve generated using the supplied protein standard. Samples treated with snake venom were used as a positive control for complement activation.
Search related documents:
Co phrase search for related documents- complement activation and human complement inhibitor: 1
- complement activation and positive control: 1, 2, 3, 4, 5
- complement activation and protein standard: 1
- complement canine and human complement: 1
- human complement and positive control: 1, 2
- inhibitor concentration and positive control: 1
- patient sample and positive control: 1, 2
Co phrase search for related documents, hyperlinks ordered by date